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Summary.-We measured the effect of 6 standard (Adriamycin, BCNU, DTIC,
melphalan, vinblastine, actinomycin D) and 3 Phase II agents (cis-platinum,
vindesine, AMSA) on melanoma colony-forming units (CFU) in soft agar from
biopsies of 50 patients with metastatic melanoma.
Melanoma CFU demonstrated marked heterogeneity in chemosensitivity to these
9 drugs. Reduction in survival of CFU below 38°, at one-tenth the pharmacologically
achievable lh concentration (our operational definition of chemosensitivity) was
obtained in only 19% of 200 in vitro trials, and was usually the same whether or not
patients had been exposed to prior chemotherapy, suggesting that melanoma CFU
are inherently resistant to presently available chemotherapeutic drugs. The soft-
agar assay was 86% accurate (25/29 cases) in identifying drugs to which the tumour
was resistant in vivo, and 63% accurate (12/19 trials) in identifying drugs to which
the tumour was clinically sensitive, counting mixed responses as responses. In
contrast, if mixed responses were classified as progressive disease, the accuracy of
identification of sensitivity fell to 42% (8/19 trials).
These investigations furnish a quantitative description of the chemosensitivity of
human metastatic melanoma CFU. Additionally, these studies serve as a useful step
towards the development of an in vitro chemosensitivity test for human melanoma,
and provide an operational quantitative basis for further exploration of in vitro-
directed therapy in metastatic neoplasms.
The treatment of metastatic melanoma
is currently unsatisfactory. The number
of anticancer drugs known to be active is
small, and they produce low response rates
with few complete remissions (Einhorn
et al., 1974). An assay to identify useful
chemotherapeutic agents in melanoma
would represent a major advance.
Hamburger & Salmon (1977) have de-
veloped a simple bi-layer agar system
which allows the growth ofhuman tumour
stem cells from a variety of tumours
(Salmon, 1980), including melanoma
(Meyskens et al., 1981). Tumour stem cells
are defined as those with self-renewal
properties which are responsible for re-
population of a tumour in vivo. In vitro
these cells can most readily be identified
by their clonogenic or colony-forming
ability. One method which functionally
identifies clonogenic cells is the tumour
stem-cell assay, which has shown con-
siderably accurate prediction of clinical
sensitivity and resistance in a variety of
human tumours (Salmon et al., 1978;
1980b; Von Hoff et al., 1981) and detailed
studies have been carried out on the use
of this assay in multiple myeloma (Durie
et al., 1981) ovarian cancer (Alberts et al.,
1980, 1981b) and other neoplasms. We
have also presented data on ovarian cancer
and malignant melanoma which suggests
that the assay may be used as an in vitro
Phase II clinical trial (Salmon et al., 1981).
In this report we describe in vitrotumour
stem-cell/in vivo clinical correlations forF. L. MEYSKENS, JR ET AL.
our first 50 patients with metastatic mela-
noma, including a variety of standard and
experimental chemotherapeutic agents,
on human melanoma stem cells. Addi-
tionally, we have examined relevant in
vitro parameters for defining chemosensi-
tivity.
MATERIALS AND METHODS
Patient studies.-All patients had meta-
static malignant melanoma, and had tumour
biopsies which were successfully cultured in
the tumour stem-cell assay. Sixty per cent
(30/50) of patients in this study had received
multidrug chemotherapy at some time before
biopsy and assay. In vitro studies were per-
formed either before chemotherapy, or at
least 4 weeks after the last course of chemo-
therapy. Only patients whose clinical trials
were evaluable forresponse, and had sufficient
in vitro data, were included in the in vitro/in
vivo correlation studies. Clinical evaluation of
response to treatment was assessed with the
standard Southwest Oncology Group criteria.
Complete response (C) represents objective
disappearance of all evidence of melanoma;
partial response (P) > 5000 regression of all
measurable disease; mixed response (M)
>50% regression of one or more evaluable
disease sites but not all sites, and improve-
ment (IMP) represents 25-50% tumour re-
gression. Lesions were measured in at least
2 dimensions and the product of the 2 maxi-
mal distances was used to determine size.
When possible, lesions were measured in 3
dimensions, and the product of the maximal
distances determined. Correlations between
in vitro and clinical responses reported in this
paper include a combination ofretrospective,
prospective, and decision-aiding trials
(Salmon, 1980). For patients receiving multi-
drug in vivo treatment, the drug with the
smallest in vitro survival was used to quanti-
tate in vitro sensitivity and classify the
patients as either in vitro sensitive orresistant.
Preparation of specimens.-Stock solutions
of intravenous formulation of Adriamycin
(ADR), 1,3-bis-chloro (2-chloroethyl)-1 nitro-
sourea (BCNU), cis-platinum (DDP), di-
methyltriazeno imidazole carboxamide
(DTIC), melphalan (PAM), velban (VLB),
actinomycin D (Act D), vindesine (VDE), and
methanesulphonamide, N-(4-(9-acridinyl-
amino)-3 methoxyphenyl) (AMSA) were pre-
pared in sterile buffered saline or water and
stored at -70°C in aliquots sufficient for
individual assays. Subsequent dilutions were
made in saline for cell incubation. Tumour-
cell suspensions were transferred to tubes and
adjusted to a final concentration of 106/ml in
the appropriate drug or control medium.
Each drug was tested at concentrations that
we calculated from pharmacokinetic data
(Alberts & Chen, 1980) as pharmacologic-
ally achievable in vivo. Final concentration
ranges (in ,ug/ml) were 0-01-0-30 for ADR,
0 05-3 0 for BCNU, 0-05-1.0 for DDP and
DTIC, 0 05-0 40 for PAM, 0-01-1-0 for VLB
and AMSA, and 0.0001-0.1 for Act D and
VDE.
Single-cell suspensions were prepared from
tumour biopsy by mechanical techniques
described previously (Hamburger & Salmon,
1977; Salmon et al., 1978). Cells were incu-
bated with or without drugs for 1 h at 37°C
in Hanks' balanced salt solution. The cells
were then centrifuged at 150 g for 10 min,
washed twice with serum-free medium and
prepared for culture. Loss of cells during this
procedure was <5% in both the control and
drug-treated samples.
Culture assay for tumour colony-forming
cells-.The culture system has been extens-
ively described (Salmon et al., 1978; Salmon,
1980; Meyskens et al., 1981). In brief, 5 x 105
cells were suspended in a lml volume of0-3%
agar containing 10% horse serum in enriched
Connaught Medical Research Laboratories
Medium 1066 and plated over a lml nutrient
feeder layer of McCoy's 5A medium with
10% heat-inactivated foetal calf serum in
0-5% agar in 35mm2 plastic Petri dishes.
Conditioned medium was not required in the
feeder layer. Plates were routinely monitored
after plating for single-cell dispersion, and all
control and drug assays were in triplicate.
Plates were scanned on Day 1 for aggregates.
Those containing aggregates were discarded,
but this is rare in melanoma as good cell dis-
persion is usual. Plates were incubated at
37°C in a humidified atmosphere containing
6% CO2 for 10-21 days. Melanoma colonies
were counted when they contained at least
30 cells, generally at about 14 days. The
cloning efficiency (PE) was 0 008-0 08%
(mean 0-015%). At least 30 colonies per con-
trol plate were required to assess the results
of chemosensitivity assays. A linear relation-
ship between the number of cells plated and
the number of colonies produced in control
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cultures has previously been demonstrated
(Meyskens et al., 1981). Below 100,000 cells
plated, it is difficult to assess linearity, since
PE is too low. However, to better assess
linearity in this cell range, we have recently
used a microtitre system and found that in
3 of 4 cases linearity was evident (Meyskens
and Thomson, unpublished results). While
higher PE can be attained with the micro-
titre system, it is less convenient for chemo-
sensitivity testing, when 35mm2 dishes are
preferable, as many colonies can be grown in
each plate and are more readily counted.
Morphology of the neoplastic-melanoma cell
colonies was further defined with a dried-
slide technique (Salmon & Buick, 1979) and
a combination of Papanicolaou and melanin
staining (Mishima, 1960). Melanoma colonies
from these patients expressed melanin pig-
mentation, which served as a marker of
neoplastic origin of the colony-forming cells
(Meyskens et al., 1981).
Data analysis.-All assay data were stored
on a Wang 2200 C laboratory computer disc
file. Cloning efficiencies were calculated from
the total number of cells plated, and were not
corrected for the proportion of non-tumour
cells in the sample. S.e. mean for individual
data points averaged 5%. For the figures, the
mean of triplicate observations of the sur-
vival of tumour colony-forming units (TCFU)
for each patient was plotted against drug
concentration. Because of practical limits on
the number of cultures that can be set up on
fresh biopsies, higher plating concentrations
were not routinely used to define drug-dose
effects at TCFU levels < 5% of control.
Previous experience with the assay has
suggested that survival of TCFU at one-
tenth the calculated pharmacologically
achievable concentration x lh ("cut-off" con-
centration) provides a useful parameter to
relate to clinical response (see Moon et al.,
1980, 1981). The "cut-off" concentrations
specified were 0 01,ug/ml for 1 h for Act D,
VDE, and VLB and 0410 ,ug/ml for lh for the
remaining drugs. These concentrations were
selected on the basis of an extensive compila-
tion of the literature (Alberts & Chen, 1980)
and our own pharmacokinetic studies. The
doses necessarily represent an approximation
to drug concentrations that would be found
in an individual patient. On the basis of
training sets of in vitro/in vivo correlations in
experiments with ovarian cancer (Alberts et
al., 1980b) and multiple myeloma (Durie etal.,
54
1981) and on the current study, patients
with melanoma were classified as sensitive if
survival ofTCFU was <38% at the "cut-off"
concentration and resistant if >38%. This
simple approach to classifying in vitro res-
ponse has developed from a careful analysis
ofthe more complex "area under the curve"
(Moon et al., 1980, 1981) and should be
viewed as an operational method of deter-
mining in vitro chemosensitivity and relating
TCFU survival to clinical response.
RESULTS
Survival of melanoma TCFU at "cut-off"
concentration
We have examined the effect of a series
of drugs on melanoma TCFU. The per-
centage survivals of melanoma TCFU at
the "cut-off" concentration of Act D
are profiled in the Figure and summarized
in Table I for the 9 drugs tested. The
Figure graphically demonstrates the
marked heterogeneity of response to a
drug of melanoma TCFU, both within a
tumour and between tumours, and the
frequent presence of a plateau of drug-
resistant TCFU even at very high drug
concentrations. Using the operational
definition of 38% TCFU survival at the
"cut-off" concentrations to define in vitro
sensitivity (Table I), the percentage of
tumour stem cells sensitive to the different
drugs were: PAM, 36%; ADR, 30%;
DDP, 27%; Act D, 26%; AMSA, 20%;
VDE, 14%; BCNU, 12%; DTIC, 9%;
VLB, 8%.
The effects on inelanoma TCFU of two
drugs with similar actions were compared.
In 4 patients (Nos 22-25) the effect of
ADR and AMSA on TCFU was simul-
taneously available. The TCFU survival
at 0-10 ,ug/ml for ADR vs AMSA were (in
%) 23 vs 19, 30 vs 56, 96 vs 18, and 111 vs
79. The effect of VLB and VDE on TCFU
was also simultaneously assessed in 8
patients (No. 33, 38, 30, 42, 45, 47, 48,
49). The percentage TCFU survival at
0*01 ,ug/ml for VLB vs VDE were (in %)
77 vs 78, 68 vs 67, 104 vs 94, 101 Vs 99,
100vs 101, 77 vs 78, 60vs 16, and 81 vs 101.
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TABLE I.-Percentage survival ofmelanoma stem cells at "cut-off" concentration of 9 drugs
Drug ,ug/ml for 1 h
ADR BCNU DDP DTIC PAMI VBL Act D VDE AMSA
Patient 0-10 0 10 010 0-10 001 0-01 0 01 001 0 10
I 1 21 -
2 - 122
3 47 73 48 56 96
4 84 84 46 40
5 47 16 72 46
6 31 49 27
7 52 75 22
8 - 50 72 33 32
9 84 96 45
10 95 101 104
11 20 47 110 83 41 62
12 101 101
13 56 70
14 67 94 92 1 22
15 58
16 69
17 92 76
18 68 94 55 54 61
19 69 53
20 64 94 90 102
21 94 63
22 23 88 26 26 88 19 19
23 30 35 89 80 95 56
24 96 51 - 78 49 104 77 18
25 111 110 122 97 91 105 79
26 60 100 88 21
27 46 20 20 85
28 29 79
29 43 24 20 87 42
30 44 15 30
31 70 66 79
32 84 101 7'3 50 86
3,3 53 34 77 23 78 94
34 40 -
35 33 45 - 39 6 49
36 86 74 82 89 69
37 90 81 78 28 72
38 60 68 44 67 104
39 72 46 33 33 45
40 52 100 104 36 94 81
42 91 81 79
42 131 114 101 104 99 102
43 72 4
44 85 38 99)
45 122 64 100 89 101 121
46 35 60 15 52 15
47 65 81 77 80 78 94
48 27 87 16 80
49 84 96 81 54 101 -
50 94 62 72 39
Sensititive* cases '3 4 3 3 4 2 11 6 6
Total cases 10 32 11 .33 11 12 36 24 30 o 30 12 5 27 9 36 16 7 30.1 25 20
* Sensitive: <380o/ .sturv-ival of TCFU.
Effect ofprior chemotherapy on the in vitro from 30 patients with prior chemotherapy
sensitivity of melanoma TCFU to drugs (Table II). There was no overall difference
One hundred and forty in vitro drug in survival of TCFU in response to in
studies were conducted on TCFU from vitro chemotherapy in those patients who
20 patients with no prior chemotherapy, had not received prior chemotherapy
and 60 studies were conducted on TCFU (26/140 tests, 19%) and those who had
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TABLE II. Effect ofprior chemotherapy on
the in vitro sensitivity of melanoma stem
cells to drugs
No prior Prior
chemotherapy chemotherapy*
Drtug
ADR
BCNU
DDP
l)TIC
PAM
VLB
Act D
VDE
AMSA
Total
(0)
0 (0)
4 (15)
1 (17)
3 (11)
2 (29)
1 (13)
8 (33)
2 (12)
5 (25)
26 (19)
R
6
22
5
24
5
7
16
14
15
114
S (%)
3 (75)
0 (0)
2 (40)
0 (0)
2 (50)
0 (0)
3 (25)
1 (13)
1 (10)
12 (20)
R
1
6
3
6
2
5
9
7
9
48
P
(Fisher)
0-033
0 566
0 424
0-578
0-333
0 666
0-402
0-683
0 301
* Piior clhemotherapy in each instance with agents
other than those tested.
(12/60, 200%). There was also no significant
difference in survival of TCFU exposed to
the 9 individual drugs tested, except for
ADR, where prior chemotherapy favoured
in vitro sensitivity.
Detection of in vitro drug sensitivity of
melanoma TCFU
Discovery of at least one effective drug
( < 38% survival ofTCFU) for each patient
is a desirable goal. We performed 282
in vitro trials using the above 9 drugs.
Table III summarizes the number of
TABLE III.-Detection of in vitro drug
sensitivity ofmelanoma stem cells*
Drugs stu(lie( Studi.es
1-2
3-4
5-6
7-8
8
11
26
10
Studies containing at
least 1 active (lrugt
1 (13)1
6 (55)
19 (73)
10 (100)
* Includes additional patients in which in1 vitro/ini
Vivo correlations were not made.
t <38% melanoma colony survival at "cut-off"
concentration.
I Using the test for tren(d in proportions (Armitage.
1971) there is a significant increase in the proportioin
of studies in which at least one sensitive drug was
found (P<0-0001).
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TABLE IV.-Effect of in vitro percentage survival range on in vitro/in vivo correlations
for Actinomycin D in metastatic melanoma
Parameter In vitro/In vivo correlation* Correlations ofvalidityt
A K r
A
In vivo True True
responset % survival § S/S S/R R/S R/R positive negative
0 83
0 83
0 83
0 66
0 33
50
40
35
30
20
5
5
5
4
2
4 1
3
2
1
0
1
1
2
4
7
8
9
10
11
0 56
0 63
0-71
0 80
1o00
0 88
0 89
0 90
0 83
0 73
* Correlation: S/S-Cases sensitive in vitro and in vivo;
S/R Cases sensitive in vitro and resistant in vivo;
R/S-Cases resistant in vitro and sensitive in vivo;
R/R-Cases resistant in vitro and in vivo. For patients receiving multidrug in vivo
treatment, the drug with the smallest in vitro survival was used to quantitate in vitro
sensitivity and classify the patient as either in vitro sensitive or resistant.
t Validity: True positive equals S/S _; True negative equals R/R S/S +S/R' TuneayeqasR/R +R/S
In vivo response equals / +S/S
§ % survival of tumour colonies at a "cut-off" concentration of 0*01 pg/ml.
studies and the number of drugs in each
investigation inrelationship to the number
and percentage of instances in which
TCFU survival was reduced to < 38%
at the "cut-off" concentration. The results
show that with more drugs tested there
was a significant increase in the proportion
of studies in which at least one effective
drug was found (P< 0 0001). For a high
probability ofdetecting at least one active
drug, at least 6 drugs should be tested in
any assay.
In vitro/in vivo correlations with Act D
We have sufficient in vitro and in vivo
clinical data with Act D to begin to assess
the relation of in vitro sensitivity to this
agent to clinical response. The correlation
of in vitro/in vivo correlations for Act D is
shown in Table IV, and includes mixed
responses as responses. The in vivo
response rate was 0 353 (S/S)/(S/S+R/S).
Above 35% TCFU survival the predicted
in vivo response was > 0-83, and fell at
lower TCFU survival (which suggested a
break-point) particularly since the true
positive (S/S)/(S/S+S/R) in vivo/in vitro
correlation continued to increase with
decreasing TCFU survival. In contrast,
the true negative (R/R)/(R/R+R/S) in
vitro/in vivo correlation was maximal
(0.90) at 35% TCFU survival. The
extended calculations indicate that 38%
TCFU survival gives the best fit of
predicted in vivo repsnse and true negative
in vitro/in vivo correlation. These results
demonstrate the method by which an
acceptable level of correlation for sensi-
tivity(S/S)/(S/S +S/R) orresistance(R/R)/
(R/R +R/S) can be determined using
percentage survival at the "cut-off" con-
centration. For example, at 50% TCFU
survival predictive accuracy for sensitivity
was 56% (5/9) and for resistance 88%
(7/8). In contrast, at a 20% TCFU survival
the predictive accuracy for sensitivity was
100% (2/2) and for resistance 73% (11/15).
Overall experience with clinical correlation
The in vitro melanoma TCFU and in
vivo clinical response were compared in
the 50 melanoma patients treated with a
variety ofanticancer drugs (Tables V, VI).
The 38% in vitro "cut off" concentration
was derived using the 48 correlations in
41 patients with melanoma. The approach
was the same as that detailed above for
Act D (Table IV) and was influenced by
the observed in vivo response rate as well
as the true positive and true negative
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TABLE V.-Correlationofinvitromelanoma
stem-cellsurvivalwithclinicalresponse*
S/st S/R
R/S
R/R$:
12 (8)
7 (11)
4 (4)
25 (25)
* In vitro sensitivity is defined as <38% colony
survival at -G the pharmacologically achievable
Ih concentration x time. In vivo sensitivity is
defined as an objective mixed, +partial+complete
response. Numbers in parentheses denote the com-
parisons when mixed clinical responses are classed
as progressive disease. S/S, S/R etc. as defined in
Table IV.
t True positive rate ((S/S)/(5/S +S/R)) x 100 = 63
(42).
t True negative rate ((R/R)/(R/R +R/S)) x 100=
86 (86).
rates associated with the in vitro/in vivo
correlations. When a clinical response was
defined as a complete, partial, or mixed
(see Materials and Methods), reduction in
survival of TCFU below 38% correlated
with clinical response in 12/19 clinical
trials (63%). If mixed responses were
regarded as progressive disease, survival
of TCFU below 38% correlated with
clinical response in 8/19 clinical trials
(42%). TCFU survival above 38% corre-
lated with clinical tumour progression
in 85% of 29 trials. Using Fisher's exact
test, there is a significant association be-
tween the in vitro and in vivo outcome,
with P= 0-001. If mixed responses are
excluded in the evaluation, P =0 06.
The details of the 12 objective clinical
responses are shown in Table VI. In 6
cases the patient had no prior therapy,
but in the other 6 the patients had pre-
viously received 1-6 drugs (mean= 3).
In 4 clinical trials only single agents were
used, and in 8 trials more than one agent
was used.
DISCUSSION
It is clear from these studies that human
melanoma TCFU exhibit marked hetero-
geneity in chemosensitivity to the 6
standard agents (ADR, BCNU, DTIC,
PAM, VLB, and Act D) and 3 Phase II
agents (DDP, VDE, AMSA) tested. Reduc-
tion in survival ofTCFU to less than 38%
at one-tenth thepharmacologically achiev-
able concentration occurred in only 19%
of 200 in vitro trials with these 9 drugs
in the 50 patients studied. These results
are, in general, similar to those obtained
in our centre for chemosensitivity testing
of ovarian cancer (Alberts et al., 1981)
and multiple myeloma (Durie et al., 1981).
However, in contrast to melanoma TCFU,
ovarian and myeloma tumour stem cells
which had not been exposed to prior
chemotherapy in vivo were much more
sensitive to chemotherapy in vitro (Durie
et al., 1981; Alberts et al., 1981). For
example, Alberts et al. (1981) found
significantly more chemosensitivity in
untreated patients than in previously
treated patients with ovarian cancer for
DDP, ADR and bleomycin.
The fact that melanoma cells from
untreated patients were no more sensitive
to the drugs tested than cells from pre-
viously treated patients (Table II) suggest
that most melanoma TCFU are inherently
resistant to presently available chemo-
therapeutic agents. Until more effective
agents are identified, the acquisition of
drug resistance or cross resistance between
agents cannot be easiy approached in
human melanoma, unless serial biopsies
were studied from individual patients.
The apparent increased sensitivity of
melanoma TCFU from patients previously
treated with ADR remains unexplained,
and merits further laboratory and clinical
investigation.
An important goal in the development
of an in vitro predictive assay is deter-
mination ofthe minimum number ofdrugs
to be tested in vitro to identify at least
one agent with a high probability ofbeing
effective in vivo. Our data indicate that
the frequency of identifying potentially
effective drugs increases with the number
of drugs tested per melanoma specimen
(Table III). If > 6 drugs were tested, a
drug producing <,38% survival at the
"cut-off" concentration was found in
all cases (10/10). On the basis of our
in vitro/in vivo correlations for melanoma
(Tables VI, VII) we can predict that
patients who are sensitive in vitro will
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TABLE VI. Characteristics ofpatients with metastatic melanoma whose tumour regressions
were predicted by in vitro drug assay
Patienit P'revious In vitro
No. therapy R
46 None DTIC
VDE
13 DTIC ADR
BCNU Act D
*HU
PAMI
ADR
Act l)
37 None DTIC
BCNU
Act D
AMSA
HU
48 BCNU Act D
*RT AMSA
24 DTIC DTIC
BCNU BCNU
Act D
ADR
PAM
VDE
14 DTIC
AMSA
35 None DTIC
PAMI
PALA
39 None BCNU
DTIC
AMSA
1 None None
22 BCNU
DTIC
HU
Act I)
*TX
VDE
27 BCNU
DTIC
Act D
TX
30 DTIC
In vivo
S Treatment
Act D DTIC
DDP Act D
AMSA
Heat Heat (42°)
(42°) +DDP
+DD)P
VD)E VDE
VLB
*BLML
HU
VDE
AMSA
VLB
BLM
AMSA
VDE
Act 1) Act D
BCNU BCNU
Act D Act D
Act, 1) 1)TIC
VDE Act 1)
DTIC
BCNU
BCNU ADR
Act D AMSA
DDP
PAM
VDE
AMSA
*MGBG
DDP
D)TIC
BCNU
AMSA
VDE AMSA
Act D VDE
DDP
BCNU AMSA AMSA
*PALA VDE VDE
Responset
C
Duration
(montlis)
Response
(lescription
10+ Complete disappearance of
multiple subcutaneous
nodules
P 7 Regression of extensive
vaginal and thigh disease
P 5+ > 50% deerease in multiple
nodal and skin nodules
P 5 > 50% decrease in lung an(d
skin nodules
1P 3 > 50% reduction of abdominal
mass
1' > 50% decrease in lung
nodules and neck nodules
P 2 > 50% decrease in lymph
nodes
P > 50% decrease in multiple
lung and skin nodules
MI 3 > 50% decrease in axillary
nodes; inguinal nodes stable
M I > 50% decrease in liver mass;
skin progression
M 2 > 50% reduction of tongue
mass, progression of
subcutaneous nodules
M 1 > 50% decrease in liver
metastases; lung nodules
stable
* HU: hydroxyurea; RT: radiotherapy; TX: tamoxifen; BLM: bleomvcin.
MGBG: methyl glyoxal bis (guanyl hydrazone). PALA: N-(phosphonoacetyl(-L-aspartate.
t C: complete; P: partial; M: mixed.
respond 40-60% of the time. Since the 35%O, this approach may be useful for drug
overall clinical response rate of metastatic selection in patients with metastatic
melanoma to the best single agents is
10-15% (Einhorn et al., 1974) and to the
best combination chemotherapy is 30-
melanoma.
The conceptual and practical steps
involved in determining in vitro TCFU
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sensitivity and obtaining clinical correla-
tions has been extensively reviewed else-
where (Salmon, 1980; Moon et al., 1980;
1981; Alberts et at., 1981). Initially, a
training set ofin vitro drug-survival curves
and clinical-response data was analysed,
and clinical sensitivity and resistance were
related to an area under the survival curve
with increasing drug concentrations in
vitro (Moon et al., 1980; 1981). Pharmaco-
logical considerations provided further
understanding of this system. Reduced
survival of TCFU at low drug concentra-
tions (< 10% of the pharmacologically
achievable Ih concentration for drugs with
a short half-life) in vitro proved important
for identifying ranges of drug concentra-
tions relevant for predicting clinical res-
ponse. This system has been furtherrefined
and operationally simplified, such that if
the pharmacology of a drug is reasonably
well known, in vitro/in vivo correlations
can be simply related to percentage sur-
vival of TCFU at the "cut-off" concentra-
tion. The use ofthis latter approach is seen
in Table IV for Act D and metastatic
melanoma. The acquisition offurther data
for specific tumours and drugs will allow
further refinement. With presently avail-
able information, < 38% colony survival
has served as a useful demarcation be-
tween clinical sensitivity and resistance.
It is important to emphasize that with
further in vitro/in vivo experience this
discrimination point may change.
Except for the higher frequency of
mixed responses in melanoma, the correla-
tion of in vitro TCFU survival and clinical
response for metastatic melanoma is very
similar to our results for ovarian cancer
(Alberts et al., 1980; 1981) multiple
myeloma (Durie et al., 1981), and a variety
ofother tumours (Salmon et al., 1980), an
observation which has been confirmed by
other groups (Von Hoff et al., 1981; Mann
etal., 1981).
Important corroborations ofourfindings
have recently been reported in studies of
human melanoma xenografts studied both
in vivo in immunodeficient mice and in
vitro in agar culture (Courtenay & Mills,
1978; Fodstad et al., 1980; Bateman et al.,
1980; Tveit et al., 1980; Selby & Steel,
1981). However, important differences
between our results and these investiga-
tors exist. Our PE is usually in the range
0-01-0-1%, whilst the PE in xenografts
and agar diffusion chambers has been
closer to 1-5%. We have also frequently
seen plateaus in colony survival with
increasing drug concentrations, while a
linear decrease in colony survival has been
recorded in the other systems. There are
innumerable possible explanations for
these differences. The most important
consideration is to determine the nature of
the "resistant" colonies in the plateau.
This plateau may be real and may rep-
resent a subfraction ofresistant clonogenic
cells which are not grown in the other
systems. Alternatively, the plateau may
represent clonogenic cells which have
receivedsublethal damage andaredestined
to die if allowed to replicate further. The
plateau "survivors" do not represent
aggregates, as they are not present within
24 h of plating, but developed and grew
in the agar and are not morphologically
distinguishable from melanoma colonies
on control plates. To directly assess the
reason for the plateau will require replat-
ing of dispersed cells from the resistant
colonies in the absence and presence ofthe
drug.
In our studies, sensitivity or resistance
to agents such as DTIC in vitro corre-
sponded with efficacy of the drug in vivo
as well. Both our studies and those of
Tveit et al. (1980) with human melanoma
xenografts, indicate that DTIC activity
in vitro is an indicator of clinical response.
Previously, there had been one report
suggesting that in vivo bioactivation was
required for DTIC (Loo et al., 1976); this
now appears less likely.
Overall, our investigations provide a
quantitative description of drug sensi-
tivity of human metastatic melanoma
TCFU to a series ofagents, with somewhat
more success than we anticipated for a
tumour that is generally considered drug
resistant. Additionally, as has also been
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the case with other neoplasms, the assay is
quite accurate (86%) in melanoma for
identifying drugs to which the tumour will
be resistant. From the clinical standpoint,
prospective identification of drug resis-
tance can spare patients needless expense
and toxicity from useless agents. The data
also suggest: (a) that meaningful clinical
responses are more likely to be associated
with a TCFU survival below 38% at low
drug concentrations, and (b) minimally
active drugs maybeidentifiedbyaccepting
higher levels of survival of TCFU. These
studies also demonstrate that drug resis-
tance in human melanoma TCFU is often
present before any drug exposure in vivo.
These observations imply that melanoma
TCFU are frequently resistant to presently
available drugs, andthateithernew classes
ornew modalities oftherapywillbe needed
to treat melanoma.
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